Journal article

CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: A new prognostic indicator?

J Ang, M Lijovic, LK Ashman, K Kan, AG Frauman

Cancer Epidemiology Biomarkers & Prevention | AMER ASSOC CANCER RESEARCH | Published : 2004

Abstract

OBJECTIVE: CD151 is the first member of the tetraspanin family to be associated as a promoter of human tumor metastasis. However, its biological function and expression phenotype among different tumors has not been well investigated. METHOD: Tissue specimens from 76 primary prostate cancers and 30 benign prostate hyperplasia (BPH) controls were obtained from the Department of Anatomical Pathology at the Austin and Repatriation Medical Centre (now Austin Health) from 1984 to 1993. We used quantitative immunohistochemical analysis to measure CD151 protein expression. Analyses of differences among BPH and prostate cancer groups were done with one-way ANOVA and Newman-Keuls test. The Kaplan-Meie..

View full abstract

University of Melbourne Researchers